Antiepileptic Drug Therapy in Children

Published on 20/04/2015 by admin

Filed under Neurology

Last modified 20/04/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 3892 times

Chapter 59 Antiepileptic Drug Therapy in Children

Rational management of antiepileptic drug therapy in children requires an understanding of pharmacokinetics, pharmacodynamics, and toxicology of these agents. Pharmacokinetics is the study of drug absorption, distribution, metabolism, and elimination: that is, what the body does to a drug. Pharmacodynamics is the study of a drug’s biochemical and physiologic effects: that is, what the drug does to the body. Children, much more than adults, have widely varying abilities to absorb, distribute, metabolize, and eliminate drugs [Rane and Wilson, 1976]. Evidence also exists that antiepileptic drug pharmacodynamics in children differ from those in adults [Henriksen, 1988]. Application of basic pharmacokinetic and pharmacodynamic principles to antiepileptic drug therapy facilitates the attainment and maintenance of targeted serum concentrations, clinical response, control of drug interactions, and optimization of clinical response.

Adverse reactions often dictate the choice of an antiepileptic drug and subsequent adjustment of therapy. An understanding of these reactions, including their differences and similarities among various antiepileptic drugs, and the application of appropriate clinical and laboratory monitoring provide the tools needed for the clinician to prescribe antiepileptic drug therapy rationally.

Pharmacokinetic Principles

Antiepileptic drug pharmacokinetics differ qualitatively and quantitatively between children and adults. Compared with adults, children, particularly neonates, have greater variability in their ability to absorb and eliminate antiepileptic drugs. Potential sources of variability are numerous, and include drug formulation, behavior (compliance, diet, substance abuse), environment, and physiology. Physiologic variability may be correlated with the general health of the patient, but also with specific factors such as gender, age, maturation, and, in a few cases, pregnancy. In the management of pediatric patients with seizures, there is a concern with the effects of age and maturation on the pharmacokinetic profile of the antiepileptic drugs. A drug’s effect on a child’s learning and behavior should also be a major determinant influencing the choice of an antiepileptic drug. Age has the most influence on antiepileptic drug elimination, metabolic pathways, and absorption. Factors such as protein binding and enzyme induction and/or inhibition are similar for children and for adults.

This chapter will review general pharmacokinetic principles and discuss the clinically relevant features of specific antiepileptic drugs. For quick reference, pharmacokinetic information for the antiepileptic drugs is summarized in tables, with absorption characteristics provided in Table 59-1, and volume of distribution, protein binding, half-life, and metabolites presented in Table 59-2 and Table 59-3.


Absorption is a complex phenomenon controlled by the physicochemical properties of the drug, the formulation, and the physiologic conditions at the sites of absorption: stomach, small intestine, colon, rectum, buccal and nasal mucosa, and muscle. Most drugs are given orally as solid formulations, which must first disintegrate into small particles that are then dissolved in the gastrointestinal fluid. Only after a drug is dissolved is it available for absorption. Most drugs are absorbed by passive diffusion of the unionized form but some drugs use active transport mechanisms. Gastrointestinal absorption is influenced by age-dependent changes in physiologic variables, such as gastric emptying time, stomach and intestinal pH, absorptive area, and gastrointestinal transit time. Food intake may affect antiepileptic drug pharmacokinetics, especially absorption. Although there is concern that the ketogenic diet may alter dosing requirements, a recent study indicated that there are no significant changes in the concentrations of several antiepileptic drugs (valproate – free or total, topiramate, phenobarbital, lamotrigine, clonazepam) during the ketogenic diet [Dahlin et al., 2006].

Absorption is described in terms of rate and extent. The term absorption half-life describes the rate at which drug reaches the systemic circulation. An indirect measure of absorption rate is the Tmax. This measure is useful in comparing the rates of absorption of different brands or formulations of the same drug. A lower (i.e., earlier) Tmax usually is an indication of a faster rate of absorption. When all other pharmacokinetic parameters are constant, a faster rate of absorption will result in a lower Tmax and higher maximum concentration (Cmax).

The extent of absorption describes the amount of a drug that reaches the blood relative to the dose. It is termed oral bioavailability (F) and is the fraction of the dose that reaches the systemic circulation. Absolute bioavailability of a drug is determined by comparing the area under the concentration vs. time curve after an oral (or rectal, intramuscular, and so on) dose with the area under the concentration vs. time curve after intravenous (IV) administration of the same drug. However, because many antiepileptic drugs do not have IV formulations, an absolute biovailability cannot be determined. Rather it can be estimated by comparing available oral formulations, termed relative bioavailability. Relative bioavailability is determined by comparing the area under the concentration vs. time curve for a specific formulation to that of a reference product. For example, the relative bioavailability of a generic brand of phenytoin sodium 100-mg capsule is measured by comparing its area under the concentration vs. time curve with that for brand phenytoin (Dilantin 100-mg capsule).

Because the hepatic portal system drains the entire gastrointestinal system (except for the distal rectum and buccal and nasal mucosa) all drugs swallowed are first delivered to the liver after crossing the gastrointestinal mucosa. Thus, a fraction of these drugs may be metabolized before entering the systemic circulation. The average plasma concentration is determined by the bioavailability and the rate of elimination (clearance) by the following relationship:


Therefore, changes in bioavailability of a drug from alterations in drug formulation, alterations in gastrointestinal physiology, or interactions with inhibitors or inducers can result in clinically significant increases or decreases in drug concentrations in plasma or at the receptor site.

Descriptors of absorption, such as Cmax and Tmax, and the bioavailability, may vary considerably among different formulations of the same drug. The relative rates of absorption, and thus Tmax and Cmax, adhere to the following order of most rapid to slowest, and highest peak concentration to lowest: solutions > suspensions > capsules > tablets > extended-release formulations [Garnett and Cloyd, 1993]. Formulation-related differences in absorption characteristics are greatly influenced by the composition of the inactive ingredients (e.g., filler, particle size of drug) and nature of the capsule or tablet coating).

Volume of Distribution

Volume of distribution (Vd) is a measurement of how the drug is distributed throughout the body (tissues and blood), and is expressed in terms of liters or liters per kilogram. Mathematically, it is expressed as the following:


where Vd is the volume of distribution and Cmax corresponds to the concentation immediately after IV administration, if this was the route of administration. Because many antiepileptic drugs do not have an IV formulation, the Vd of these is estimated from the concentration at Tmax. Vd values may differ markedly among antiepileptic drugs because drugs distribute to tissues with different binding characteristics. For example, drugs that concentrate in fat tissue have relatively low plasma concentrations, but may have a Vd value measured in the hundreds of liters because the Cmax is low. Changes in body composition, such as increases or decreases in fat, muscle, or water, may thus alter Vd values.

Vd is very useful for calculating loading doses. The purpose of a loading dose is to fill body compartments rapidly to reach a targeted plasma concentration and thus a targeted concentration at the site of action. The equation for calculating a loading dose is the following:


The change in plasma concentration term denotes the desired increase after administration of the loading dose. For example, if a patient has a plasma concentration of 5 mg/L and the target concentration is 20 mg/L, the desired change in concentration is 15 mg/L. For phenytoin, the Vd is approximately 0.75 L/kg, so an IV dose of 11.25 mg/kg is required. When loading doses are administered intramuscularly, orally, or rectally, resultant maximum plasma concentrations are usually less than after IV loading, owing to slower and incomplete absorption and the elimination of some drug during the absorption phase. Table 59-4 presents loading dose information for six major antiepileptic drugs.

Protein Binding

Several antiepileptic drugs are highly bound to one or more plasma proteins, most commonly albumin or α1-acid glycoprotein. Drug assays usually measure the total concentration of drug, which is the sum of the bound and unbound concentrations. The free fraction is the ratio of unbound to total plasma drug concentration:


In general, only the unbound drug is able to cross the blood–brain barrier and is in equilibrium with brain and spinal fluid (Figure 59-1; see also Table 59-3). Consequently, clinical response and toxicity correlate better with the unbound drug concentration than with the total drug concentration. For drugs that have limited protein binding (less than 50 percent) or a constant ratio of unbound to total concentration, measurement of total plasma concentrations is a reliable indicator of response. However, if a drug is highly protein-bound (greater than 85 percent), measurements of total concentrations may be an unreliable guide to clinical outcomes. The fraction bound may change because of illness, age, or other drugs that compete for binding sites. In these circumstances, it may be necessary to measure the free concentration to understand the clinical effect better. Low-extraction drugs are those that have only a small portion of the drug metabolized by each pass through the liver. Most of the antiepileptic drugs are low-extraction drugs and alterations in protein binding do not affect the steady-state concentration of the unbound drug. Thus, adjustments in dose generally are not necessary when protein binding is altered because the unbound concentrations remain unchanged. Erroneously increasing the dose when total levels are low, but unbound levels have not changed, will likely result in toxicity.

Metabolism and Elimination

Antiepileptic drugs are eliminated from the body through metabolism and renal excretion. Clearance (Cl) and elimination half-life (t½) are the pharmacokinetic terms that quantitatively describe drug elimination. Clearance describes the rate of elimination and defines dosage requirements, whereas t½ is useful in determining time to steady state and dosing intervals.

Clearance is the volume of blood from which drug is removed (cleared) per unit of time. It is identical conceptually and mathematically to the more familiar physiologic parameter of creatinine clearance. For antiepileptic drugs that are eliminated by the liver, clearance is determined by the free concentration of the drug and the intrinsic ability of hepatic enzymes to metabolize the unbound drug. Although, for most drugs, clearance is proportional to dose, some drugs exhibit nonlinear pharmacokinetics in which clearance changes with concentration (Figure 59-2).

The following points are important to remember:

The t½ is the time required for the plasma concentration to decline by 50 percent. Half-life is determined by both distribution volume and clearance:


Thus, t½ is not a direct measure of Cl, but is useful in calculating the time to reach steady state or the time required for drug elimination. After initiation or modification of therapy or after any change in clearance, 5 half-lives must elapse for a new steady-state plasma concentration to be reached (see Figure 59-2). The time required to attain steady state can be explained by using the definition of t½. The plasma concentration in the body declines 50 percent in 1 t½; therefore, the percentage of drug remaining in the body, as indicated by the plasma concentration after 2, 3, 4, and 5 half-lives, is 75 percent, 87.5 percent, 93.75 percent, and 96.875 percent, respectively. The actual amount of drug remaining in the body and the additional amount of drug removed in subsequent half-lives are so small (after 5 half-lives) that, for practical purposes, it can be ignored. However, the rate of decline is most rapid in the first two half-lives, and the risk of seizures is greatest during this period.

Biotransformation (metabolism) of medications is accomplished through biochemical reactions. These reactions create compounds that are more polar (more water-soluble) and are eliminated from the body, usually through the kidneys. Phase I reactions (e.g., using the cytochrome P-450 system) involve oxidation and reduction. Phase II reactions (non-cytochrome P-450-mediated) couple the drug or its metabolite with endogenous substrates by conjugation or synthesis. The endogenous substrate may be glucuronic acid, glutathione, glucose, sulfate, or acetate, making the drug more polar and hence water-soluble [Capparelli, 1994]. Antiepileptic drugs may undergo metabolism by phase I or II reactions, or a combination of both. As persons mature, the pathways may change and the metabolite profile will be altered.

In the neonate, phase I reactions, such as hydroxylation and, to a lesser extent, dealkylation, are significantly depressed [Anderson and Lynn, 2009]. In older children, however, phase I activity generally exceeds that in adolescents or adults. As a general rule, the rate of drug metabolism reaches a peak at 0.5–2 years of age and then declines in an exponential manner, reaching adult values in early adolescence. As an example, the clearance of valproic acid, in which metabolism includes both phase I and phase II reactions, is fastest in young children and then declines to reach adult values at the age of approximately 12–15 years. Also, its metabolism shifts from phase II to phase I reactions.

For most drugs, the evaluation of maturation-related (as contrasted with chronologic age-related) enzymatic clearance has not been studied systematically. It is likely that some of the variance in drug clearance noted in children of the same age is due to differences in maturational development. As children grow, the dose may need to be increased to compensate for the increased body (and liver) mass, but later re-adjusted for the decline in phase I and II reactions.

Active metabolites formed after biotransformation of the parent compound can contribute significantly to desired and toxic effects of the parent drug. Metabolites exist in both bound and unbound states. Only the unbound metabolite is available for elimination or biotransformation to an inactive metabolite. As with unbound parent drug, the unbound metabolite concentration in the plasma most closely correlates with the concentration of metabolite at the site of action. The presence of active metabolites complicates interpretation of plasma drug concentrations and clinical response. As with the parent drug, the relationship between unbound and total metabolite concentrations can be disrupted by displacement from serum proteins or changes in metabolism. In fact, parent or metabolite concentrations may be altered independently by drug interaction or physiologic change in metabolism. Table 59-5 displays the cytochrome P-450 isoform families involved in antiepileptic drug metabolism, along with known inducers and inhibitors.

Renal elimination is accomplished by glomerular filtration and/or renal tubular secretion. Glomerular filtration rate and renal tubular function in newborns are less efficient than in adults [Linday, 1994]. After 1 year of age, glomerular filtration rate, corrected for body surface area, is the same as for older children and young adults. Renal tubular function reaches adult values, normalized to body surface areas, within several months. Decreases in clearance can be better correlated with sexual maturity than with chronologic age. Making correlations with physiologic or sexual maturation and developmental age, rather than chronologic age, may be helpful in accounting for the variability observed in clearance of drugs that are renally eliminated [Finkelstein, 1994].

Specific Antiepileptic Drugs


The carbamates are organic compounds derived from carbamic acid, NH2COOH. Some have been found effective for the treatment of epilepsy. Carbamazepine is the oldest of this class; oxcarbazepine and, more recently, eslicarbazepine acetate, have been added to this category.


Carbamazepine is a very water-insoluble, neutral compound with a slow dissolution rate in gastrointestinal fluid. The relative bioavailability is similar for all four formulations (i.e., suspension, chewable tablet, extended-release, and regular tablet), ranging from 75 to 90 percent, although marked intrapatient and interpatient variability has been observed [Faigle and Feldmann, 1975; Maas et al., 1987]. In children on maintenance therapy, the rate of absorption is much faster for the suspension than for tablet formulations, resulting in a significantly earlier Tmax and higher Cmax (Figure 59-3). This property occasionally produces transient concentration-dependent central nervous system side effects. Administering the same daily dose in smaller amounts and giving it more frequently may correct this problem. Sustained-release preparations may permit twice-a-day dosing, eliminating the need for administration of medications during school hours. This improves medication compliance and decreases central nervous system side effects because peak concentrations will be lower. Studies conducted by the U.S. Food and Drug Administration have demonstrated that carbamazepine tablets are significantly less well absorbed after being exposed to high humidity [Meyer et al., 1992; Wang et al., 1993]. These findings emphasize the importance of storing all antiepileptic drugs at room temperature in a dry location.

The Vd in children for carbamazepine based on oral preparations ranges from 0.8 to 2.0 L/kg. Both carbamazepine and its active metabolite, carbamazepine-10,11-epoxide, are bound to several plasma proteins [Eichelbaum et al., 1975; Rawlins et al., 1975]. Approximately 65–85 percent of carbamazepine and 30–60 percent of carbamazepine-10,11-epoxide are bound to albumin. Both also bind to the reactant protein α1-acid glycoprotein. Binding to α1-acid glycoprotein increases after physiologic stress, such as from burn injuries or inflammatory diseases (e.g., juvenile rheumatoid arthritis). Increased binding to α1-acid glycoprotein can increase total carbamazepine and carbamazepine-10,11-epoxide concentrations without necessarily increasing the unbound drug concentrations. In such situations, patients may have total concentrations above the desired range but have no side effects. Adjusting dosage is not necessary; plasma concentrations return to baseline as α1-acid glycoprotein declines.

Carbamazepine is eliminated primarily by phase I cytochrome P-450-mediated metabolism (see Table 59-5), forming an active metabolite (10,11-epoxide). Carbamazepine displays dose-dependent elimination pharmacokinetics, in which dosage increases produce a less than proportionate increase in steady-state total concentration (see Figure 59-2). Carbamazepine metabolism undergoes autoinduction, in which clearance increases over time after exposure to the drug. Within 30 days after beginning therapy, carbamazepine clearance may increase by as much as 300 percent. Further increases in maintenance doses may result in further induction [Kudriakova et al., 1992]. In some children, induction causes plasma carbamazepine concentrations to remain unchanged or even decline, despite increasing doses up to 40–50 mg/kg per day [Curatolo et al., 1988]. Carbamazepine and carbamazepine-10,11-epoxide metabolism also can be induced by phenytoin or phenobarbital, resulting in as much as a 100 percent increase in clearance [Kerr and Levy, 1989]. Initial carbamazepine t½ ranges from 10 to 20 hours, but the t½ decreases because of autoinduction to 4–12 hours. Consequently, many children require three or four doses a day to maintain targeted plasma concentrations. Sustained-release preparations help overcome this problem.


Oxcarbazepine is rapidly absorbed, with a Tmax of less than 1 hour after a single oral dose. Absorption is nearly 100 percent. It is a prodrug that is converted extensively to 10,11-dihydro-10-hydroxy-carbamazepine (the monohydroxy derivative), which is the active compound. Less than 2 percent of the area under the concentration–time curve is attributed to the parent compound, and approximately 70 percent to the monohydroxy derivative. Only the monohydroxy derivative is measured for therapeutic monitoring [Theisohn and Heimann, 1982]. Co-administration of oxcarbazepine and food leads to an increase in the bioavailability and maximum plasma concentration; however, Tmax remains unchanged. The slight changes in the absorption parameters with food administration do not appear to be clinically significant [Degen et al., 1994].

The major advantage of oxcarbazepine is that it is not metabolized to the active epoxide metabolite, which is believed to contribute to the side-effect profile of carbamazepine. Both the parent drug and its metabolite are lipophilic, which facilitates their movement across the blood–brain barrier. The monohydroxy derivative has a volume of distribution of 0.7–0.8 L/kg [Feldmann et al., 1977; Theisohn and Heimann, 1982], and both oxcarbazepine and the monohydoxy derivative bind to plasma proteins at approximately 60 percent and 40 percent, respectively [Klitgaard and Kristensen, 1986; Patsalos et al., 1990].

Approximately 96 percent of an oral dose is eliminated in the urine, with less than 1 percent of oxcarbazepine being excreted unchanged. The greater part of the dose is conjugated and excreted as the glucuronide (9 percent oxcarbazepine glucuronide and 49 percent monohydroxylated glucuronide) [Lloyd et al., 1994; Schutz et al., 1986]. Unlike carbamazepine, oxcarbazepine does not appear to induce its own metabolism [Larkin et al., 1991].


Eslicarbazepine acetate is a voltage-gated channel blocker that was approved in Europe in 2009. Approval in the US is still pending. Its chemical structure is similar to both carbamazepine and oxcarbazepine [Benes et al., 1999]. It differs from carbamazepine in that it does not produce an epoxide metabolite or exhibit autoinduction. Eslicarbazepine acetate is a prodrug that undergoes first-pass hydrolytic metabolism to cleave the acetate group to form the active entity – eslicarbazepine, which is the S(+) enantiomer of licarbazepine (also known as the S(+)10-monohydroxy metabolite of oxcarbazepine) [Almeida et al., 2008b]. It appears to exhibit linear pharmacokinetics and is metabolized to a glucuronidated metabolite via several uridine diphosphate glucuronosyltransferases [Loureiro and Fernandes-Lopes, 2008]. One study in 29 children and adolescents (ages 2–17 years) shows dose-proportional pharmacokinetics [Almeida et al., 2008a]. Both a suspension and scored tablets of strengths 200 mg, 400 mg, 600 mg, and 800 mg were available in the study. The daily doses used in the study ranged from 5 to 30 mg/kg/day. The Tmax was between 0.5 and 3 hours. Eslicarbazepine acetate was cleared faster in younger children as compared to adolescents, although Cmax was similar among all age groups.


Approximately 95 percent of a dose of felbamate is absorbed in adults after oral administration. Absorption of the drug is fairly rapid, with Tmax values ranging from 1 to 4 hours [Wilensky et al., 1985]. The Vd of felbamate is approximately 0.8 L/kg [Devinsky et al., 1994; Wilensky et al., 1985]. Distribution of felbamate is fairly uniform throughout the entire body. It binds mainly to albumin (22–25 percent), and the amount of binding is dependent on albumin concentration [Perhach and Shumaker, 1995].

About 90 percent of felbamate is eliminated in the urine. Approximately 40–50 percent of the absorbed dose is eliminated as the unconjugated parent compound, and up to 58 percent is found as metabolites and conjugates [Shumaker et al., 1990]. Felbamate is cleared at a faster rate in children. Population pharmacokinetic analysis of data from 139 pediatric patients gives clearance values approximately 40 percent higher in younger children (2–12 years of age) than those in older children and adults (13–65 years).

Gamma-Aminobutyric Acid Analogues

Gabapentin and pregabalin were initally conceived as drugs that may modulate gamma-aminobutyric acid (GABA) receptors. However, this is not their main mechanism of action.


The absolute bioavailability after oral administration of gabapentin is 60 percent [Vollmer et al., 1986]. Absorption is linear up to daily doses of 1800 mg, after which bioavailability begins to decline, decreasing to 35 percent at daily doses of 4800 mg [Richens, 1993]. Gabapentin uses the l-amino acid transporter system in the gut to enter the body. This system is saturable and the dependence of gabepentin on it may explain the decrease in bioavailability with increasing doses above 1800 mg [Stewart et al., 1993].

Gabapentin has a Vd of approximately 0.6–0.8 L/kg [Richens, 1993] and does not bind to plasma proteins [Vollmer et al., 1986]. To enter the brain, gabapentin uses the l-amino acid transporter system, which is also saturable [Luer et al., 1999].

Gabapentin is eliminated renally. Clearance in children aged 1 month to 12 years was well correlated with creatinine clearance. Clearance was higher in children younger than 5 years of age, necessitating a 30 percent higher dose to attain equivalent concentrations as observed in children age 5 and older and in adults [Haig et al., 2001; Ouellet et al., 2001]. It does not have any significant pharmacokinetic interactions.


Pregabalin is rapidly absorbed. Its bioavailability is greater than 90 percent. Unlike gabapentin, pregabalin demonstrates no changes in absorption as dose increases. Pregabalin does not bind to plasma proteins and is not metabolized in humans, with 98 percent of the dose recovered unchanged in urine [Brockbrader et al., 2000]. Like gabapentin, it does not appear to interact with other antiepileptic drugs. There were no changes in trough steady-state concentrations of concomitant antiepileptic drugs (phenytoin, lamotrigine, or valproic acid) when pregabalin was co-administered. Likewise, there were no changes in pregabalin concentrations after administration of carbamazepine, phenytoin, lamotrigine, or valproic acid [Brodie et al., 2005]. It should be noted that there did appear to be a decrease in pregabalin exposure when it was given with phenytoin; however, this was thought to be due to a possible food effect with pregabalin. Because pregabalin is eliminated mostly via the kidneys, doses may need to be adjusted in children with decreased renal function.


The hydantoins include ethytoin, mephenytoin, and phenytoin and its prodrug fosphenytoin. Although used in the past, ethytoin and mephenytoin are not widely used now.


Phenytoin is a poorly water-soluble compound and is often formulated as a sodium salt. It is available as a suspension, chewable tablet, capsule, and a parenteral formulation. The nonlinear, saturation pharmacokinetics of phenytoin can make even small differences in dose clinically significant. The chewable tablet and the suspension contain phenytoin acid, whereas the capsules and the IV formulation contain phenytoin sodium, which is equivalent to only 92 percent of the acid (see Table 59-1). Thus, two 50-mg chewable tablets deliver 8 percent more phenytoin than a 100-mg phenytoin sodium capsule. The suspension is available in a 125-mg/5-mL strength. In the past, the reliability of the suspension has been questioned owing to its tendency to settle. It has been demonstrated that some agitation is sufficient to permit delivery of the specified amount of drug [Sarkar et al., 1989]. Unexpected fluctuations in plasma phenytoin concentrations associated with the use of suspensions likely have been the result of pharmacokinetics rather than formulation problems. Intramuscular injection of the parenteral solution (with a pH of 11) is contraindicated because it results in precipitation of drug that is then slowly and erratically absorbed [Kostenbauder et al., 1975]. It is also painful and causes tissue necrosis [Serrano and Wilder, 1974]. Phenytoin capsules are available in both prompt-release and extended-release formulations. Patient and family education about the differences in phenytoin dosage forms is important to maintain optimal therapy.

Bioavailability, Tmax, and Cmax are altered when large amounts of phenytoin are given as a single oral loading dose, presumably because of the formation of a multicapsule concretion. In a study involving six healthy adults, absorption was reduced by 10–15 percent and Tmax increased from 18 to 32 hours, when phenytoin sodium capsules were given in single dose of 10 mg/kg or more [Jung et al., 1980]. Dividing the total loading dose into 5-mg/kg doses given every 2–3 hours overcomes this problem. The most rapid way to attain therapeutic plasma concentrations after oral loading is to use prompt-release phenytoin sodium capsules or suspension [Goff et al., 1984].

Some reports have suggested that phenytoin is poorly absorbed in newborns because of irregular gastric emptying time, relatively high gastric pH (greater than 4), or decreased absorptive surface [Morrow and Richens, 1989; Morselli, 1983; Painter et al., 1978]. Other evidence indicates that formulation-related differences in absorption, nonlinear pharmacokinetics, and age-dependent changes in elimination account for much of the variability in plasma concentrations [Dodson, 1984].

Phenytoin Vd in children and adolescents is approximately 0.7 ± 0.1 L/kg [Koren et al., 1984]. The relatively small variability in phenytoin Vd permits precise calculation of loading doses. For example, a 15-mg/kg loading dose given intravenously will result in a postinfusion mean concentration of 20 mg/L, with a range of 15–25 mg/L. Phenytoin is also highly protein-bound to albumin.

Phenytoin undergoes extensive hepatic metabolism. A small fraction, 5 percent or less, is excreted unchanged [Battino et al., 1995]. It is metabolized by a saturable cytochrome P-450 enzymatic pathway. Phenytoin follows Michaelis–Menten or saturable elimination kinetics (see Figure 59-2). As the plasma concentration rises, phenytoin clearance decreases, owing to saturation of enzymatic metabolism. Therefore, increases in dose result in disproportionately greater increases in steady-state plasma concentration.

Phenytoin half-life also varies with plasma concentration. As plasma concentration rises, the half-life increases. Half-life ranges from 8 to 12 hours at low concentrations to more than 60 hours at concentrations above 20 mg/L. At concentrations within or above the therapeutic range, 1–4 weeks may be required to reach steady state.

Phenytoin metabolism in neonates is reduced compared with that in older children. Within days to weeks after birth, the rate of metabolism accelerates, reaching a maximum in the 0.5- to 3-year age range. Children in this age group require the highest mg/kg daily doses (Figure 59-4). Thereafter, metabolism and dosage requirements decline gradually, reaching adult values during adolescence. Figure 59-5 illustrates that even minor alterations in dosage produce disproportionately large changes in plasma concentration. Therefore, small adjustments in daily dose are indicated as the plasma concentration approaches or exceeds Km, which usually falls in the range of 5–10 mg/L. Use of the scored 50-mg chewable tablet, the 30-mg phenytoin sodium capsule, or the suspension facilitates making such adjustments in dose.


Fosphenytoin is a prodrug of phenytoin that is rapidly hydrolyzed by tissue and red blood cell alkaline phosphatases to phenytoin. Due to the rapid conversion to phenytoin, the pharmacokinetic information for phenytoin and not fosphenytoin is what is clinically relevent. Fosphenytoin is water-soluble and is formulated as a nontoxic, parenteral solution. The pharmacokinetics of phenytoin derived from fosphenytoin are identical to phenytoin given directly [Leppik et al., 1989]. Fosphenytoin is packaged as milligram phenytoin equivalents and is well tolerated when given intramuscularly.

Fosphenytoin absorption, not its conversion to phenytoin, appears to be the rate-limiting step in achieving therapeutic phenytoin levels. The mean half-life of fosphenytoin is 8 minutes after IV administration [Donn et al., 1987; Gerber et al., 1988; Leppik et al., 1989] and 33 minutes after intramuscular injection [Leppik et al., 1990]. Age does not affect the phosphatase enzyme responsible for the conversion of fosphenytoin to phenytoin. Fosphenytoin is more avidly bound to albumin, compared with phenytoin, resulting in brief increases of free phenytoin concentrations after infusion [Hussey et al., 1990; Jamerson et al., 1990]. The observed decrease in total phenytoin concentrations returns to those expected when the conversion from fosphenytoin to phenytoin is completed; therefore, monitoring of plasma concentrations should be done about 1 hour after IV administration of fosphenytoin. Unlike phenytoin, fosphenytoin can be given intramuscularly and avoids serious tissue necrosis from extravasation of IV phenytoin. Its major uses are treatment of status epilepticus and maintenance therapy when oral administration is not possible.


Lacosamide (known as harkoside in earlier studies) was approved for use in the United States during 2009. It is completely and rapidly absorbed with a bioavailability of 100 percent [Hovinga, 2003]. Lacosamide appears to follow linear pharmacokinetics and its Cmax is between 1 and 4 hours after an oral dose [Hovinga, 2003]. There does not seem to be a food effect on lacosamide pharmacokinetics [Kellinghaus, 2009]. Protein binding has been shown to be less than 15 percent. Lacosamide is metabolized to an inactive desmethyl metabolite, which is then cleared along with the parent drug via the kidney. Lacosamide is not approved for use in young children at this time; however, there is at least one clinical trial that is investigating the safety and pharmacokinetics in children with partial seizures between the ages of 2 and 17 years. Doses being studied are 8–12 mg/kg/day.


Lamotrigine has a bioavailability approaching 100 percent. Its Tmax occurs 2–3 hours after administration of a single oral dose. With doses in the range of 15–240 mg, Tmax and area under the concentration–time curve are directly proportional to dose [Yuen and Peck, 1987]. The Vd of lamotrigine is approximately 1.5 L/kg in children [Chen et al., 1999]. It is distributed uniformly throughout the body, and approximately 55 percent of lamotrigine is bound to plasma proteins [Garnett, 1997].

Lamotrigine is extensively metabolized to an inactive glucuronide by an inducible uridine diphosphate (UDP) glucuronyltransferase reaction [Lamictal, 2004]. Clearance is greater in younger children [Battino et al., 2001]. Infants (younger than 2 months of age) metabolize lamotrigine more slowly, and metabolic rates increase during the first year of life [Mikati et al., 2002]. Estrogen-containing oral contraceptives may cause dramatic cyclical fluctuations of blood levels (decreasing during the estrogen phase and rebounding in the placebo week), and levels decrease dramatically during pregnancy [Pennell et al., 2008]. There may be an impact of age on lamotrigine concentrations [Reimers et al., 2007]. However, data for weight were not available in a majority of the patients and the effect of age could be due to the fact that older children weigh more than younger children [Reimers et al., 2007].


Levetiracetam is extremely water-soluble and has an oral bioavailability of close to 100 percent. Its Cmax is within 2 hours of dose administration. When the drug is administered with food, the rate of absorption is decreased, but the extent of absorption is unchanged. Therefore, levetiracetam can be administered without regard to timing of meals. Levetiracetam also exhibits linear pharmacokinetics after single doses ranging from 250 up to 5000 mg [Patsalos, 2000]. The Vd for levetiracetam is 0.5–0.7 L/kg, and protein binding is less than10 percent. Two-thirds of a dose is eliminated unchanged and the rest is eliminated as an inactive metabolite in the urine [Keppra package insert, 2004]. The clearance is 30–40 percent higher in children than in adults [Chhun et al., 2009; Glauser et al., 2007; May et al., 2003; Pellock et al., 2001]. Results are now available from studies in children as young as 2 months old and they confirm that the half-life of levetiracetam in younger children is approximately 5–6 hours, shorter than that seen in adults [Glauser et al., 2007]. An IV formulation and a sustained-release formulation are now on the market. It may be possible to give levetiracetam rapidly. Patients (4–32 years of age) who temporarily lost the ability to take medications by mouth were given an IV loading dose of levetiracetam via rapid infusion (given within 6 minutes). Levetiracetam concentrations ranged from 14 to 189 μg/mL and no significant changes in blood pressure or significant abnormalities in the electrocardiogram were experienced [Wheless et al., 2009]. There were also no local infusion site reactions noted; however, the formulation was diluted 1:1 with normal saline or dextrose 5 percent in water (D5W).

Drug–drug interaction information in children indicates that the concentrations of carbamazepine, valproic acid, topiramate, or lamotrigine are similar between study groups who receive levetiracetam or placebo [Otoul et al., 2007].


Rufinamide is slowly absorbed due to the fact that it is lipophilic and dissolves slowly in aqueous solutions. The bioavailability is nonlinear and decreases at higher doses, with doses of 1600 mg producing less than proportional concentrations. Steady-state doses of 200, 400, and 800 mg produced morning trough concentrations of 2.81, 5.23, and 11.0 μmol/L, whereas 1600-mg doses resulted in a mean trough concentration of 19.6 μmol/L (4.7 mg/L) [Elger et al., 2010; Limite, 2005; NoAuthors, 2005]. Dissolution is the rate-limiting step in absorption; therefore, changes in gastrointestinal environment, such as with the presence of food, could have an effect on the absorption of rufinamide. It is suggested that rufinamide be administered with food. Rufinamide exposure is increased by 31–34 percent and the Cmax by 36–56 percent when the drug is given after high-fat meals [Perucca et al., 2008]. Rufinamide is metabolized to inactive metabolites via the carboxylesterase pathway. Although rufinamide does not appear to be metabolized via the cytochrome P-450, the carboxylesterase enzymes can be induced by inducers of the CYP450 enzymes. Rufinamide also appears to be a weak inhibitor of CYP2E1 and a weak inducer of CYP3A4.

Pharmacokinetic data in children are beginning to appear in the literature. The majority of the data concerning rufinamide is on file with the manufacturer; however, data on these trials have been summarized in Perucca et al. [2008]. A dosing regimen for children has been simulated from several phase II and III clinical studies involving patients with partial or generalized seizures and one study with Lennox–Gastaut syndrome patients. The simulation included 119 children (aged less than 12 years) and 99 adolescents (12–17 years) [Marchand et al., 2010], and was used in supporting material presented to the European Agency for the Evaluation of Medicinal Products. These studies involved patient populations and the presence of inducing and inhibiting polytherapy. Children who weigh less than 30 kg had greater variability in simulated rufinamide exposure measures than those children who were heavier than 30 kg. In addition, the co-administration of valproate resulted in higher rufinamide plasma concentrations. This study proposed a maximum daily dose of 600 mg for children who also receive valproic acid, and a maximum daily dose of 1000 mg for those children who do not also receive valproic acid. Indeed, valproic acid increased rufinamide steady-state plasma concentrations from 54.9 percent in male children and 70.1 percent in female children in a population pharmacokinetic study that is on file at Eisai [Perucca et al., 2008]. The increase in concentrations when valproic acid was a co-medication was approximately 3 times higher in children than in adults. (Adult concentrations were 15 percent higher.) Population studies involving children have also identified increases in rufinamide’s apparent clearance values due to the presence of inducing co-medications. Known antiepileptic drug inducers, such as carbamazepine, phenobarbital, phenytoin, or primidone, as well as vigabatrin, decreased rufinamide steady-state plasma concentrations in children from 23 to 46 percent [Perucca et al., 2008].


Oral bioavailability of tiagabine is greater than 90 percent, and the bioavailability of tablets and that of the oral solution appear to be similar [Mengel et al., 1991a]. The absorption rate for tiagabine is reduced up to 65 percent when the drug is administered with food, although the extent of absorption is not affected [Mengel et al., 1991b]. Tiagabine has a Vd of 0.74–0.85 L/kg [Gustavson et al., 1997], and protein binding is approximately 96 percent [Gustavson et al., 1997; Ostergaard et al., 1995]. Tiagabine has a half-life of 5–9 hours [Gustavson and Mengel, 1995]. Tiagabine undergoes extensive metabolism by means of the cytochrome P-450 3A isoform, but no active metabolites have been identified. As observed with other drugs, clearances in children are faster than in adults; adjusting both Vd and clearance values according to body size gives values similar to those seen in adults [Gustavson et al., 1997].


Oral tablets of topiramate have a relative bioavailability of approximately 80 percent that of an oral solution. It is rapidly absorbed, with a Tmax of approximately 2 hours [Easterling et al., 1988]. Overall absorption is not affected by co-administration with food [Doose et al., 1992]. The protein binding of topiramate is less than 15 percent [Ben-Menachem, 1995a], and its Vd is 0.6–0.8 L/kg [Johannessen, 1997]. Elimination is mainly through the kidney, although a portion of the dose is removed by the liver [Ben-Menachem, 1995a]. Preliminary observations in pediatric patients indicate that the mean oral topiramate clearance is 44–55 percent higher in children, and they may need a higher dose than adults to achieve a similar plasma concentration [Adin et al., 2004; Glauser, 1997].

Valproic Acid

Valproic acid appears to be completely absorbed from all the available products (except for the extended-release formulation), but the rate of absorption varies significantly with dosage form (see Table 59-1). Its Tmax is 0.5–1 hour after ingestion for the syrup, 0.5–2 hours after the capsule, 1–6 hours for the enteric-coated tablet, and 3–6 hours for the sprinkle capsule [Cloyd et al., 1983, 1985, 1992]. Absorption after ingestion of the enteric-coated tablet is delayed for several hours; during this lag phase, plasma concentrations may continue to decline. Food further delays, but does not decrease, valproic acid absorption from the enteric-coated tablet [Fischer et al., 1988]. The extended-release tablet has an absolute bioavailability of 90 percent [Dutta et al., 2004]. The extended-release tablets and the enteric-coated tablets are not interchangeable. The extended-release tablets need to be prescribed at a dose that is 8–20 percent higher than the enteric-coated dose to attain similar plasma concentrations [Dutta and Zhang, 2004]. An IV formulation is also available and has been studied in children. The IV formulation should not be given intramuscularly due to toxic muscle necrosis [Gallo et al., 1997].

Valproic acid distribution volumes vary more than those of carbamazepine, phenobarbital, or phenytoin, and range from 0.12 to 0.49 L/kg. When loading doses are calculated, a volume of 0.2 L/kg is recommended. Valproic acid protein binding to albumin is saturable. At concentrations below 40–50 mg/L, the bound fraction averages 90–95 percent. As total concentration rises to the upper boundary of the therapeutic range, the percentage bound falls to 80–85 percent. Saturable protein binding results in a nonlinear relationship between total valproic acid concentration and dose. Unbound valproic acid concentrations, however, remain linear with dose [Cloyd et al., 1993; Riva et al., 1983]. The percentage of unbound valproic acid can be unpredictable and unusually high after rapid infusion in children who are critically ill [Birnbaum et al., 2003].

Valproic acid is extensively metabolized to both active and inactive metabolites. Principal pathways include glucuronidation, β-oxidation in the mitochondria, and oxidation through cytochrome P-450. The monounsaturated metabolites 2-ene-valproic acid and 4-ene-valproic acid possess anticonvulsant activity; the 2-ene-valproic acid achieves pharmacologically relevant concentrations in the brain. 2-Ene-valproic acid accumulates in the brain more slowly than does valproic acid, which may account for the slow onset and cessation of valproic acid anticonvulsant activity. Although the diunsaturated metabolite 2,4-diene-valproic acid, is a potent hepatotoxin, its role in valproic acid hepatotoxicity remains unclear.

The elimination half-life of valproic acid is short. In the first few weeks after birth, half-life ranges from 17 to 40 hours, but rapidly declines from 3 to 20 hours in infants and young children. The full antiepileptic effect of valproic acid is obtained days to weeks after steady state is reached, and this effect continues for some time after the drug is discontinued. The lingering effect may be partly the result of its inhibitory effect on the enzymes responsible for the degradation of GABA, or may be due to the accumulation of 2-ene- valproic acid. This prolonged duration has prompted some investigators to propose single daily dosing [Stefan et al., 1984]; however, with other proposed mechanisms of action, seizure control is related to plasma valproic acid concentrations. Under these circumstances, dosing at least every half-life is indicated to minimize fluctuations in plasma concentrations. When valproic acid is given as monotherapy, the half-life may be long enough to maintain therapeutic concentrations for up to 24 hours in some children. Such children may be able to take valproic acid once a day [Cloyd et al., 1985].


Vigabatrin is a 50:50 racemic mixture of R(−) and S(+) enantiomers, with the S(+) enantiomer responsible for the drug’s pharmacologic activities and toxic effects [Haegele et al., 1983; Rey et al., 1990]. Bioavailability is approximately 75 percent in adults when the drug is given orally and is similar for both the tablet and the solution [Hoke et al., 1991]. Administration of vigabatrin with food does not significantly affect vigabatrin pharmacokinetics [Frisk-Holmberg et al., 1989]. Vigabatrin has been studied in children [Rey et al., 1989, 1990], and bioavailability appears to be somewhat lower in children than in adults [Rey et al., 1992]. Vigabatrin does not bind to plasma proteins, and it has an apparent Vd of 0.8 L/kg [Ben-Menachem, 1995b]. Clearance or the dose to concentration ratio of vigabatrin appears to be greater in children than in adults, indicating that a higher dose is needed in children to achieve a particular concentration when compared to adults [Armijo et al., 1997].

Most of a vigabatrin dose appears unchanged in the urine. Studies in infants and children show that the half-life of the inactive R(–) enantiomer, but not the half-life of the active S(+) enantiomer, increases with linear age. Vigabatrin exerts its pharmacologic effect by irreversible inhibition of GABA transaminase, causing increases in synaptic GABA concentrations by inhibiting its breakdown. Because the half-life of GABA transaminase is much longer than that of vigabatrin itself, the pharmacologic effect is determined by the half-life of the enzyme [Ben-Menachem, 1995b; Jung et al., 1977].


Buy Membership for Neurology Category to continue reading. Learn more here